Amita Gupta, M.D., M.H.S.

Headshot of Amita Gupta
  • Chief, Division of Infectious Diseases, Johns Hopkins School of Medicine
  • Professor of Medicine

Languages: English, French, Hindi, Spanish


HIV/AIDS, Infectious Disease, Infectious Diseases, Infectious Diseases and International Health, Tuberculosis, Women's Health more

Research Interests

Global Health, Infectious Diseases, Emerging Infections, COVID-19, TB, HIV and Co-Infection Care and Treatment Clinical Trials in India and Other Resource-Constrained Countries; Mother-to-Child Transmission Prevention; Diarrheal Diseases Epidemiology; Malnutrition and TB-HIV Coinfection in Adults and Children; Antimicrobial Resistance more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment


The John G. Bartlett Specialty Practice

Appointment Phone: 443-287-6217
1717 E. Monument Street
The Park Building, Ground Floor
Baltimore, MD 21287
Phone: 410-955-1725 | Fax: 443-287-4173
The John G. Bartlett Specialty Practice - Google Maps


Dr. Gupta is Director of the Division of Infectious Diseases at the Johns Hopkins School of Medicine. She is also Deputy Director of the Center for Clinical Global Health Education (CCGHE), Faculty Co-chair of the Johns Hopkins India Institute, and Professor of Infectious Diseases at the JH School of Medicine, with a joint appointment in International Health at the JH Bloomberg School of Public Health.

Dr. Gupta specializes in international public health, clinical research, and education in infectious diseases, HIV/AIDS, tuberculosis (TB), and antimicrobial resistant infections. Since 2003, her work has been focused primarily on India, where she leads several Indo-JHU research collaborations. She serves in leadership positions as Co-Chair of the Faculty Steering Committee of the Johns Hopkins India Institute, Center Director for the Johns Hopkins Precision Medicine Center for Excellence for COVID-19, the US chair for the Indo-US Vaccine Action Program sponsored RePORT India TB research consortium, which is funded by the US National Institutes of Health (NIH) and the government of India, Department of Biotechnology. She also serves on the global RePORT International Executive Committee, a multilateral global consortia for TB research. She is Co-principal Investigator of the NIH-funded Baltimore-Washington-India HIV and Infectious Diseases Clinical Trials Unit (BWI-CTU), and she is an active clinical investigator in multi-country trials conducted by the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Trials Network (IMPAACT), and has served as protocol chair for high impact studies that have resulted in publications in The New England Journal of Medicine and The Lancet. She is Co-chair of the NIH and AmFAR funded IeDea HIV/TB Working Group and Scientific Committee co-Chair for IMPAACT TB.

She has been awarded research grants from the NIH, CDC, UNITAID, and several philanthropic foundations to investigate infectious diseases of importance to India and beyond. Learn about CCGHE India Research Partnerships In 2019, Dr. Gupta was appointed by the US Health and Human Services Secretary for a 4-year term to the NIAID Council, the chief advisory committee for National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health. In 2020, she was invited to the Governing Board of the Indo-U.S. Science & Technology Forum.

Dr. Gupta is an author of more than 200 peer-reviewed research publications and 7 book chapters on prevention and treatment of HIV, TB, and other infectious diseases, primarily in low- and middle-income settings. She has also mentored more than 35 junior scientists in India and the US to run research studies and submit their own scientific findings to peer-reviewed publications.

Dr. Gupta received an undergraduate degree from MIT, a Doctor of Medicine from Harvard Medical School, and a Master of Health Sciences in clinical investigation from JH Bloomberg School of Public Health. She completed her internal medicine training at San Francisco General Hospital-University of California, San Francisco, followed by a post-doctoral fellowships with the Epidemic Intelligence Service at the US Centers for Disease Control and Prevention (CDC, Foodborne and Diarrheal Diseases) and at the JHU School of Medicine (Infectious Diseases). more


  • Chief, Division of Infectious Diseases, Johns Hopkins School of Medicine
  • Faculty Co-chair, Johns Hopkins India Institute
  • Director, Division of Infectious Diseases, Johns Hopkins School of Medicine
  • Professor of Medicine

Departments / Divisions

Centers & Institutes



  • MD; Harvard Medical School (1997)


  • Internal Medicine; University of California San Francisco School of Medicine (2000)


  • Infectious Diseases; Johns Hopkins University School of Medicine (2005)

Board Certifications

  • American Board of Internal Medicine (Infectious Disease) (2005)

Research & Publications


Lab Website: Amita Gupta Lab

Clinical Trial Keywords

Tuberculosis; HIV; PMTCT; Breastfeeding; Antiretroviral; MDR-TB; Maternal and Infant Health

Clinical Trials

  • ACTG 5273: Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT)

  • ACTG 5274: Phase IV, Open Label Strategy Trial: REMEMBER: Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens

  • ACTG 5300/IMPAACT 2003: Phase III, Open Label, Multi-center Trial: Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

  • IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-tuberculosis Drugs during Pregnancy and Post-partum

  • IMPAACT 1077B/1077FF: Promoting Maternal and Infant Survival Everywhere (PROMISE): Breastfeeding and Formula Feeding Versions

  • IMPAACT 1078: Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High TB Incidence Settings

  • IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with OBR for MDR-TB in HIV-Infected and Uninfected Children with MDR-TB

  • The Pharmacokinetics, Safety and Acceptability of New Child-Friendly Formulations of Clofazimine and Moxifloxacin in Children Routinely Treated for Rifampicin-Resistant Tuberculosis (CATALYST)

  • Epidemiologic Factors Associated with TB Treatment Outcomes Across RePORT International Consortia

  • Dynamics and Immune Mechanisms of QFT Response in Close Contacts of TB Cases

  • A Nanopore Biosensor for Leveling MTB  Antigens in Blood

  • Effect of Neighborhoods and Peer Networks on Substance Use and Violence Among Adolescents Living with and Without HIV in India

  • Impact of Tuberculosis Infection on HIV-1 Antibody Response (NWCS501)

  • Pharmacokinetic Assessment of MDR-TB Drugs in the Treatment of TB Meningitis

  • Identification of Biomarkers That Can Predict Progression from Latent Tuberculosis Infection to Active Tuberculosis Disease

  • Tuberculosis (TB) Aftermath

  • Mental Health Outcomes among Health Care Professionals Involved in the Treatment and Care of COVID 19 Patients in India

  • Hybrid Trial for Alcohol Reduction among People with TB and HIV in India

  • Pregnancy Associated Immune Responses to Tuberculosis and HIV in India and South Africa (PARTHISA)

  • Increasing Market and Public Health Outcomes Through Scaling Up Affordable Access Models of Short Course Preventive Therapy for TB (IMPAACT4TB)

  • T Cell Biomarkers and T-regulatory Responses to Pediatric TB

  • Inflammasome Genetics and Tuberculosis Treatment Outcomes

  • Evaluation of a Urinary Biomarker Assay for Diagnosis and Test of Cure for Tuberculosis

  • Characterization of Genomics and Metabolomics among Individuals Highly-Exposed, but Resistant to MTB Infection

  • Host RNA Expression for Diagnosis and Monitoring of Pediatric TB in Africa and India

  • Immune Responses and Effect of Disulfiram on MTB Infected PBMCs as a Potential Host Directed Therapy

  • Validating a Novel Functional Correlate of Immune Protection of Tuberculosis

  • Assessing Psychological Distress among Tuberculosis Patients and Their Household Members

  • Molecular Signatures of Tuberculosis-Diabetes Interaction: Transcriptomics AND METABOLOMICS Study

  • The Role of Innate Immunity in the Acquisition of Sterile Protection against TB Infection

  • Validation of Transcriptional Signature to Predict Active TB Disease among Advanced HIV Patients

  • Biomarkers for Tuberculosis Diagnosis and Treatment Response

  • Residual Respiratory Impairment Following Pulmonary Tuberculosis

  • Implementing the Comprehensive Unit-based Safety Program to Reduce Healthcare-Associated Sepsis in the Neonatal Intensive Care Unit in Pune, India

  • Evaluating the Source of Neonatal Bloodstream Infections due to Classically Hospital Acquired Pathogens in the Neonatal Intensive Care Unit in Pune, India

  • Healthcare-Associated Sepsis in the Neonatal Intensive Care Unit in Pune, India

  • Vaginal Microbiota in HIV Infected and Uninfected Pregnant Women (Stand Alone)

  • Assessing the Feasibility and Acceptability of a Computer-based Avatar-delivered Alcohol Reduction Intervention

  • Gut Microbiota of HIV Infected Pregnant Women

  • Investigating Maternal Antibodies to Modify Infant Tuberculosis Acquisition

  • Vaginal Microbiota in HIV Infected Pregnant Women

  • Impact of Immune Changes of HIV and Stages of Pregnancy on Tuberculosis

  • Optimizing Treatment to Improve TBM Outcomes in Children

  • Markers of Lung Impairment in HIV-TB Coinfected Indian Adults

  • Assessment of Depression and Anxiety among HIV-infected Adolescents in Pune, India

  • Assessment of Cardiovascular Health Knowledge, Preventive Practices and Cardio-protective Behavior among HIV-infected Individuals in Pune, India

  • TREAT Asia Observational Database

  • Prevalence and Risk Factors for Oral Cancer among HIV-Infected Adults

  • Prevalence Survey of Risk Factors for Tuberculosis and Non-communicable Diseases in an HIV-positive Population in Pune, India

Selected Publications

View all on PubMed

Gupte AN, Kumar P, Araújo-Pereira M, Kulkarni V, Paradkar M, Pradhan N, Menon P, Chandrasekaran PD, Hanna LE, Yogendra Shivakumar SVB, Rockwood N, Du Bruyn E, Karyakarte R, Gaikwad S, Bollinger R, Golub J, Gupte N, Viswanathan V, Wilkinson RJ, Mave V, Babu S, Kornfeld H, Andrade BB, Gupta A. Baseline IL-6 is a biomarker for unfavorable tuberculosis treatment outcomes: a multi-site discovery and validation study. Eur Respir J. 2021 Oct 28:2100905. doi: 10.1183/13993003.00905-2021. Epub ahead of print. PMID: 34711538.

Garibaldi BT, Fiksel J, Muschelli J, Robinson ML, Rouhizadeh M, Perin J, Schumock G, Nagy P, Gray JH, Malapati H, Ghobadi-Krueger M, Niessen TM, Kim BS, Hill PM, Ahmed MS, Dobkin ED, Blanding R, Abele J, Woods B, Harkness K, Thiemann DR, Bowring MG, Shah AB, Wang MC, Bandeen-Roche K, Rosen A, Zeger SL, Gupta A. Patient Trajectories Among Persons Hospitalized for COVID-19 : A Cohort Study. Ann Intern Med. 2021 Jan;174(1):33-41. doi: 10.7326/M20-3905. Epub 2020 Sep 22. Erratum in: Ann Intern Med. 2021 Jan;174(1):144. PMID: 32960645; PMCID: PMC7530643.

Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T, Vhembo T, Stranix-Chibanda L, Onyango-Makumbi C, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Mave V, Rouzier V, Hesseling A, Shin K, Zimmer B, Costello D, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019 Oct 3;381(14):1333-1346. PMID: 31577875.

Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia JV, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE for the BRIEF TB/A5279 Study Team. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380:1001-1011. DOI: 10.1056/NEJMoa1806808.

Mave V, Chandanwale A, Kagal A, Khadse S, Kadam D, Bharadwaj R, Dohe V, Robinson ML, Kinikar A, Joshi S, Raichur P, McIntire K, Kanade S, Sachs J, Valvi C, Balasubramanian U, Kulkarni V, Milstone AM, Marbaniang I, Zenilman J, Gupta A. High Burden of Antimicrobial Resistance and Mortality Among Adults and Children With Community-Onset Bacterial Infections in India. J Infect Dis. 2017 Apr 15;215(8):1312-1320. doi: 10.1093/infdis/jix114. PMID: 28329303; PMCID: PMC5853545.

Contact for Research Inquiries

600 N. Wolfe Street
Phipps 521
Baltimore, MD 21287 map
Phone: 410-502-7696

Academic Affiliations & Courses

Graduate Program Affiliation

International Health, Bloomberg School of Public Health

Activities & Honors


  • 2018 Johns Hopkins School of Medicine 125th Anniversary “Living the Hopkins Mission” Honoree


  • Infectious Diseases Society of America
  • American Medical Association
  • American Society of Tropical Medicine and Hygiene
  • The International Union Against Tuberculosis and Lung Disease (The Union)

Professional Activities

  • Vice Chair, IMPAACT TB Scientific Committee
  • Member, ACTG TB transformative Science Group
  • Co-Chair, NIH/Indian Government TB Research Consortium (RePORT)
  • Chair, IMPAACT P1078, A Randomized Clinical Trial to Evaluate the Safety of Immediate (antepartum-initiated) Versus Deferred Reduction in TB Incidence and Mortality Among HIV-Infected Women and Their Infants in High TB Incidence Settings
  • Vice Chair, ACTG 5274, Reducing Early Mortality Among Patients with Advanced HIV Disease: A Randomized Strategy Trial Comparing the Safety and Efficacy of an Individualized Patient TB Treatment Approach to a Public Health Pre-emptive TB Treatment Approach in Resource-Limited Settings (REMEMBER)
  • Vice Chair, ACTG 5279, Phase III Clinical Trial of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Adults with Latent Tuberculosis Infection
  • Member, ACTG TB Transformative Science Group
  • Vice Chair, IMPAACT TB Scientific Committee
  • Co-Chair, PHOENIX ACTG A5300/IMPAACT 2003 feasibility study and MDR TB contact prophylaxis trial
  • Member, Union Interest Group in Maternal-Infant TB working group
  • Chair, IeDEA TB working group
  • Member, Executive Committee, RePORT International
  • Member, NIAID Advisory Council
  • Governing Board Member, Indo-US Science and Technology Forum (IUSTTF)
  • Faculty, JH COVID-19 CROWN registry research
  • Faculty Co-chair, Johns Hopkins India Institute

Videos & Media

Recent News Articles and Media Coverage

Amita Gupta Named Director of Johns Hopkins Medicine's Division of Infectious Diseases, (Newswise) Feb 3, 2022

Johns Hopkins Students and Faculty Members Confront India's COVID-19 Crisis. Johns Hopkins MedicineJuly 8, 2021

7 Lessons We've Learned from this Pandemic to Remember for the Next One. SELFJune 22, 2021

India COVID-19 Outbreak Could 'Spread Around the World,' Expert Warns. International Business Times May 13, 2021

Indian Students in US Anxious about COVID-19 Back Home. VOA News. May 13, 2021

Johns Hopkins University Helping India Fight Covid Surge. CBS Baltimore. May 13, 2021

Johns Hopkins expert Dr. Amita Gupta on India's covid 19 challenge & future preparedness options. Financial Express. May 12, 2021

India's COVID-19 Disaster May Be Turning Into an Even Bigger Global Crisis. TIMEMay 12, 2021

How the US can help the COVID crisis in India. The Hill. May 4, 2021

India's crushing COVID caseload the result of 'perfect storm' of factors, experts say. USA Today. April 28, 2021

As COVID Crisis Unfolds in India, Johns Hopkins Rushes to Help. Johns Hopkins HubApril 28, 2021

A Bold New Chapter Begins for Hopkins and India. Johns Hopkins HubApril 26, 2021

Trump Briefly Leaves Hospital for Photo Op With Supporters. New York MagazineOctober 4, 2020

Johns Hopkins Researchers Publish COVID-19 'Prediction Model.' Johns Hopkins MedicineSeptember 23, 2020

Study Shows Extent, Danger of TB Exposure, Part 1. Medical Daily. August 24, 2020

International Johns Hopkins Study Says Broad Measures needed to Prevent TB Spread in India. Johns Hopkins Research Story Tip. August 6, 2020

In Women with HIV, TB Preventive Therapy Poses Greater Risk in Pregnancy than Postpartum. NIH Press Release. October 2, 2019

Is this you? Edit Profile
back to top button